Synovitis is common in knee osteoarthritis (OA) and can be quantified using dynamic contrast-enhanced MR imaging (DCE-MRI). There is a strong rationale for therapeutic targeting of synovitis in OA, and imaging biomarkers derived from DCE-MRI may help evaluate response in clinical trials.
Here we evaluate the test-retest repeatability, ability to discriminate between OA (n = 14) and age-matched controls (n = 6) and 6-month responsiveness to change of three DCE-MRI biomarkers: Ktrans, IAUCĀ60, and synovial tissue volume.
Ktrans demonstrated the best repeatability, discrimination and sensitivity to change suggesting that it is the optimal DCE-MRI biomarker for use in clinical trials.
This abstract and the presentation materials are available to members only; a login is required.